Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease

Summary

To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8 mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH patients) with hypertension

Timeline

Start

2021-10-29

Primary completion

2023-02-28

Completion

2023-06-30

Publications

• Iwaki M, Kessoku T, Tanaka K, Ozaki A, Kasai Y, Yamamoto A, Takahashi K, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Kobayashi N, Saito S, Nakajima A. Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study. BMJ Open. 2022 Jul 12;12(7):e060335. doi: 10.1136/bmjopen-2021-060335.

Drugs

Indications